Mitsubishi Gas Chemical and Veritas In Silico file patent for nucleic acid drug targeting lncRNA H19
- Application 2026-179989 filed by Mitsubishi Gas Chemical and Veritas In Silico.
- Target is long non-coding RNA H19, linked to cancer cell proliferation, invasion, metastasis and treatment resistance.
- Drug candidate was discovered using Veritas In Silico’s aibVIS AI-driven drug discovery platform.
- Mitsubishi Gas Chemical launched AXELPHEX CRDMO for nucleic acid API manufacturing in October 2025 to support development.
Patent filing
Mitsubishi Gas Chemical Company and Veritas In Silico have filed patent application 2026-179989 for a nucleic acid drug and its use, covering a substance developed under their joint research announced July 3, 2025.
Technology and target
The invention is a nucleic acid therapeutic targeting lncRNA H19, which has been reported to contribute to cancer cell proliferation, invasion, metastasis and treatment resistance. The candidate emerged from use of aibVIS, Veritas In Silico’s AI-evolved drug discovery platform that upgraded ibVIS in 2026 to accelerate and improve structure screening.
Corporate context
Mitsubishi Gas Chemical acquired an equity stake in Veritas In Silico in 2017 and has positioned medical and food as strategic areas under its "Grow UP 2026" medium-term plan ending March 2027. To accelerate development and manufacturing, the company launched the AXELPHEX CRDMO service for nucleic acid drug APIs in October 2025 and is advancing joint business with Hokkaido System Science Co., Ltd.
Next steps
Both firms plan to secure patent rights and pursue commercialization with the stated aim of contributing to medical care and improving patients’ quality of life.
Source: Mitsubishi
